Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01776554 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
A Phase 2 study of Pandemic H5N1 Influenza, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 2
- Development phase
- 662
- Enrollment target
- 12
- Study locations
NCT01776554 is a Phase 2 study of Pandemic H5N1 Influenza that has completed, run by Novartis Vaccines. The registered enrollment target is 662 participants. The trial reports 12 study locations across 8 states.
The verdict
NCT01776554, a Phase 2 study of Pandemic H5N1 Influenza, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 662 participants
- Enrollment target
- 12
- Study locations
Study Summary
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
Conditions Studied
Interventions
- BIOLOGICAL Adjuvanted H5N1 pandemic influenza vaccine
Study Locations (12)
Kansas
- 7 Heartland Research Associates - Newton
- 5 Heartland Research Associates - Wichita
- 9 Heartland Research Associates - Wichita
Utah
- 8 Foothill Family Clinic - Salt Lake City
- 4 Foothill Family Clinic - South Cottonwood Heights
Other
- 75 Phramongkutklao Hospital - Bangkok
- 76 Faculty of Tropical Medicine Mahidol University - Bangkok
Florida
- 3 Meridian Clinical Research - Miami
Missouri
- 1 Saint Louis University - St Louis
Nebraska
- 6 Meridian Clinical Research - Omaha
Texas
- 10 Tekton Research - Georgetown
Washington
- 2 Rockwood Clinic P S - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01776554
The ClinicalTrials.gov registry entry for NCT01776554 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 662 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pandemic H5N1 Influenza appearing as the primary indexed condition, and to 1 intervention - of which Adjuvanted H5N1 pandemic influenza vaccine is the first listed.
NCT01776554 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Kansas, Utah, Other.
Frequently Asked Questions
What is clinical trial NCT01776554 about?
NCT01776554 is a clinical study titled "Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children". Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
What is the current status of trial NCT01776554?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 662 participants. The study started on 2013-01. Estimated completion is 2014-06.
What conditions does trial NCT01776554 study?
This clinical trial studies the following conditions: Pandemic H5N1 Influenza.
What interventions are being tested in trial NCT01776554?
The interventions under investigation include: Adjuvanted H5N1 pandemic influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01776554?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01776554 being conducted?
This trial has 12 study locations across Florida, Kansas, Missouri, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.